| Name | Title | Contact Details |
|---|
The West Wireless Health Institute is one of the first medical research organizations in the world supporting the exploration and application of wireless technologies to advance infrastructure independent health care.
Alva/Amco Pharmacal Co is a Niles, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MCD is a quality, solution oriented manufacturer of adhesive coated films, pouches, tapes, and special purpose products. MCD is ISO 13485:1996 Certified. Operating from it's GMP compliant Woodbury, Minnesota facility, MCD develops, markets, and
MDIC is the one place where industry, non-profits, academia & government can collaborate to make patient access to new medical device technologies faster, safer and more cost-effective. MDIC is a public-private partnership facilitating collaboration within the medical device industry. We coordinate the development of methods, tools, and resources used in managing the total product life cycle of a medical device to improve patient access to cutting-edge medical technology.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.